Swedish healthcare company BioGaia has launched chewable tablets with Lactobacillus reuteri Protectis and vitamin D. Launched through its partner Medhouse AB, the products – BioGaia Protectis D3 and BioGaia Protectis D3+ – will soon be available at selected pharmacy chains around Sweden.
BioGaia Protectis with added vitamin D is available in two different doses, D3 and D3+. D3 contains 10 micrograms of vitamin D, which covers the daily intake recommended by the Swedish National Food Agency for people under the age of 75. D3+ contains 20 micrograms of vitamin D and is intended for adults over the age of 75 years and adults with limited exposure to sunlight or those who, for other reasons, do not receive enough vitamin D.
“I am very pleased that we are now launching new products together with Medhouse and look forward to building the BioGaia brand also in our local market. Vitamin D deficiency is common among people living in the North, especially during the winter months. Therefore, it is logical that we now choose to introduce products containing both our patented lactic acid bacteria L. reuteri Protectis and vitamin D,” says Axel Sjöblad, Managing Director at BioGaia.
In November 2017, a number of studies underlined the health benefits of Biogaia’s products. Supplementation with BioGaia’s Lactobacillus reuteri ATCC PTA 6475 probiotic strain was found to decrease bone loss in older women, according to the results of a randomized, double-blind, placebo-controlled study at the University of Gothenburg. Moreover, rapid diagnostic testing in combination with Lactobacillus reuteri Protectis supplementation has been linked to a significant increase in height and significantly less recurrent diarrhea in a study of 71 infants with acute diarrhea, as compared to standard care and placebo treatment.